SUPERNUS PHARMACEUTICALS, INC. (SUPN)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 165,453 | 149,824 | 175,689 | 168,325 |
| Selling, general and administrative | 93,551 | 89,944 | 69,753 | 85,904 |
| Research and development | 22,115 | 26,927 | 29,036 | 26,183 |
| Cost of goods sold | 16,827 | 15,763 | 17,583 | 17,916 |
| Contingent consideration loss (gain) | - | 7,660 | -1,016 | -4,355 |
| Amortization of intangible assets | 20,819 | 19,786 | 19,488 | 20,108 |
| Total costs and expenses | 153,312 | 160,080 | 134,844 | 145,756 |
| Operating earnings | 12,141 | -10,256 | 40,845 | 22,569 |
| Interest and other income, net | 4,528 | 4,425 | 4,098 | 3,733 |
| Total other income (expense), net | 4,528 | 4,425 | 4,098 | 3,733 |
| Earnings before income taxes | 16,669 | -5,831 | 44,943 | 26,302 |
| Income tax expense (benefit) | -5,830 | 5,996 | 6,446 | 6,386 |
| Net earnings | 22,499 | -11,827 | 38,497 | 19,916 |
| Basic (in dollars per share) | 0.4 | -0.21 | 0.7 | 0.36 |
| Basic (in shares) | 56,024,771 | 55,864,692 | 55,149,760 | 54,978,781 |
| Diluted (in dollars per share) | 0.4 | -0.21 | 0.69 | 0.36 |
| Diluted (in shares) | 56,643,189 | 55,864,692 | 56,016,350 | 55,724,283 |